Furthermore, the relationship between ASXL1 mutations and inflammation or atherosclerosis remains poorly understood, though it is hypothesized that the myeloid bias seen in ASXL1 CHIP carriers may produce effects similar to those seen with TET2 loss-of-function mutations [19]. The gene discussed is ASXL1; the disease is atherosclerosis.